What is Kerendia classified as?
Kerendia (finerenone) is classified as a non-steroidal selective mineralocorticoid receptor antagonist [1].
What is the mechanism of action for Kerendia?
Kerendia works by blocking the overstimulation of mineralocorticoid receptors caused by elevated aldosterone levels. This mechanism helps to reduce inflammation and fibrosis in the kidneys and heart [2][3].
What medical conditions is Kerendia approved to treat?
Kerendia is approved to treat adults with chronic kidney disease (CKD) associated with type 2 diabetes [1]. The drug aims to reduce the risk of kidney disease progression and cardiovascular outcomes in this patient population [4].
When was Kerendia approved by regulatory bodies?
The U.S. Food and Drug Administration (FDA) approved Kerendia in July 2021 [5].
What are the potential side effects of Kerendia?
Common side effects reported for Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and diarrhea [1]. Patients are monitored for potassium levels during treatment [3].
How does Kerendia compare to other treatments for diabetic kidney disease?
Kerendia represents a novel therapeutic approach as a non-steroidal antagonist, distinct from older steroidal mineralocorticoid receptor antagonists. Its selective action is designed to mitigate some of the side effects associated with previous classes of drugs [2][3].
Are there any specific patient populations or contraindications for Kerendia?
Kerendia is contraindicated in patients with adrenal insufficiency or hypersensitivity to finerenone [1]. It is also not recommended for individuals with severe kidney impairment or those on certain medications that can significantly increase potassium levels [3].
What is the patent status of Kerendia?
Information on the patent status of Kerendia and its potential for generic competition can be found on DrugPatentWatch.com [6]. Patents play a crucial role in the commercial lifecycle of prescription drugs, influencing their market exclusivity and the eventual introduction of generic alternatives.
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215799s000lbl.pdf
2. https://www.nejm.org/doi/full/10.1056/NEJMoa2023307
3. https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia
4. https://www.bayer.com/en/news-releases/2021/bayer-receives-us-approval-for-kerendia-finerenone-the-first-and-only-
5. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-drug-treat-patients-chronic-kidney-disease-associated-type-2-diabetes
6. https://drugpatentwatch.com/